The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries

The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries

Background: Until more data are available to shed light on the thyroid disorders related to immune checkpoint inhibitors (ICPi) implemented for the treatment of hematological malignancies, the decision-making is guided by pertinent data derived mostly from solid tumors. Methods: The present review p...

Full description

Bibliographic Details
Main Authors:	Maria V. Deligiorgi, Sofia Sagredou, Lampros Vakkas, Dimitrios T. Trafalis
Format:	Article
Language:	English
Published:	MDPI AG 2021-10-01
Series:	Cancers
Subjects:	anti-CTLA-4 monoclonal antibodies anti-PD-1 monoclonal antibodies anti-PD-L1 monoclonal antibodies immune checkpoint inhibitors immune-related adverse events
Online Access:	https://www.mdpi.com/2072-6694/13/21/5277

Similar Items

A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors
by: Maria V. Deligiorgi, et al.
Published: (2023-04-01)

Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MiceSummary
by: Simon Wabitsch, et al.
Published: (2021-01-01)

Immune Checkpoint Glycoproteins Have Polymorphism: Are Monoclonal Antibodies Too Specific?
by: Mehrsa Jalalizadeh, et al.
Published: (2023-01-01)

Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer
by: Bernardo L. Rapoport, et al.
Published: (2021-10-01)

Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies
by: Brian A. Baldo
Published: (2022-02-01)

Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients
by: Anissa Roger, et al.
Published: (2018-07-01)

DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES
by: E. L. Nasonov, et al.
Published: (2017-04-01)

Immunotherapy in cancer: a combat between the tumor and the immune system; you win some, you lose some.
by: Florencia Paula Madorsky Rowdo, et al.
Published: (2015-03-01)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
by: Omoruyi Credit Irabor, et al.
Published: (2022-09-01)

The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
by: Anna Vaisman-Mentesh, et al.
Published: (2020-08-01)

Large-scale production of monoclonal antibodies in suspension culture /
by: 271860 Backer, M. P., et al.

Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy
by: Mona Yazdani, et al.
Published: (2020-08-01)

Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
by: Sadique A. Javed, et al.
Published: (2024-04-01)

A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1 Antibody-Safety and Effectiveness of Pirfenidone
by: Haiming YU, et al.
Published: (2021-07-01)

The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials
by: Amin Daei Sorkhabi, et al.
Published: (2023-12-01)

Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer
by: Mojgan Naghizadeh Dehno, et al.
Published: (2020-04-01)

Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
by: Silvia Vivarelli, et al.
Published: (2020-08-01)

Monoclonal antibodies : the second generation /
by: 186276 Zola, Heddy
Published: (1995)

Camrelizumab plus zoledronic acid showed sustained efficacy in a patient with cranial and spinal metastases from lung adenocarcinoma
by: Chu Zhang, et al.
Published: (2021-06-01)

PD-1 monoclonal antibodies enhance the cryoablation-induced antitumor immune response: a breast cancer murine model research
by: Ze-Peng Yu, et al.
Published: (2023-12-01)

Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
by: Laura Boyero, et al.
Published: (2020-12-01)

Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer
by: Yun Hu, et al.
Published: (2023-01-01)

Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
by: Zhiyu HUANG, et al.
Published: (2015-11-01)

Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails
by: Hui Zhou, et al.
Published: (2019-05-01)

Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report
by: Tanja Fetter, et al.
Published: (2024-03-01)

Penghasilan Hibridoma yang Merembeskan Antibodi Monoklon Terhadap Hormon Tiroksin (T4)
by: Yahya, Siti Romlah
Published: (1994)

PREPARATION AND PROPERTIES OF MURINE ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES RECOGNIZING PRIMARY RABBIT POLYCLONAL ANTIBODIES AGAINST MORPHINE DERIVATIVES
by: A. V. Trofimov, et al.
Published: (2019-12-01)

Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01)

Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study
by: Chuanliang Cui, et al.
Published: (2023-02-01)

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety
by: M. T. Corasaniti, et al.
Published: (2023-12-01)

Process scale purification of antibodies /
by: Gottschalk, Uwe
Published: (2009)

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
by: Katrijn Broos, et al.
Published: (2019-06-01)

Anti–PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment
by: Yonghong Hua, et al.
Published: (2022-02-01)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
by: Vishwanatha R. A. P. Reddy, et al.
Published: (2019-12-01)

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
by: Adil Parvez, et al.
Published: (2023-12-01)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
by: Ai L, et al.
Published: (2020-09-01)

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
by: Simona Camorani, et al.
Published: (2020-09-01)

Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244
by: Alexander M. Horspool, et al.
Published: (2023-04-01)

Monoclonal antibodies in cervical malignancy-related HPV
by: Parisa Shiri Aghbash, et al.
Published: (2022-10-01)

Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis
by: Bin Wang, et al.
Published: (2018-08-01)